Welcome to our dedicated page for Actuate Therapeutics news (Ticker: ACTU), a resource for investors and traders seeking the latest updates and insights on Actuate Therapeutics stock.
Actuate Therapeutics, Inc. (NASDAQ: ACTU) is a clinical-stage biopharmaceutical company developing elraglusib, a small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β), for high-impact, difficult-to-treat cancers. The ACTU news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how Actuate’s oncology programs evolve over time.
Recent news from Actuate emphasizes clinical data for elraglusib across multiple tumor types. The company has reported that its randomized Phase 2 Actuate-1801 Part 3B trial in first-line metastatic pancreatic ductal adenocarcinoma met its primary endpoint, with a statistically significant overall survival benefit for elraglusib plus gemcitabine/nab-paclitaxel compared with chemotherapy alone. Additional updates describe immune and genomic biomarker findings that may help explain responses and guide future studies.
News items also highlight elraglusib’s activity in other settings, including a Phase II trial in recurrent, metastatic salivary gland carcinoma and the Actuate-1902 Phase 1/2 study in refractory pediatric cancers such as Ewing sarcoma and neuroblastoma. Actuate has announced complete and partial responses, durable stable disease, and biomarker associations that support further development in these rare and challenging indications.
Beyond clinical results, ACTU news covers corporate and regulatory milestones, such as public and private financings, registration statements, and collaborations. Examples include a securities purchase agreement for common stock and warrants, an underwritten public offering of common stock, and a collaboration with Incyte Corporation and UPMC Hillman Cancer Center to evaluate elraglusib with retifanlimab and modified FOLFIRINOX in advanced pancreatic cancer.
Investors and followers of biotechnology and oncology can use the Actuate Therapeutics news page to monitor trial readouts, regulatory plans, financing transactions, and partnership updates related to the company’s GSK-3β–targeted cancer programs.
Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers through GSK-3β inhibition, has announced that its President & CEO, Daniel Schmitt, will ring the Nasdaq opening bell on August 23, 2024. This ceremony marks the company's recent IPO and its new status as a Nasdaq-listed company.
The event, starting at approximately 9:15 am ET, will be held at the Nasdaq MarketSite Tower in New York City. Schmitt will be joined by members of Actuate's team, Board of Directors, Scientific Advisory Board, and guests. The ceremony will be live-streamed on Nasdaq's X and Facebook pages, allowing wider audience participation in this significant corporate milestone.